PHASE 2 STUDY OF THE SAFETY AND TOLERABILITY OF MARAVIROC-CONTAINING REGIMENS TO PREVENT HIV INFECTION IN MEN WHO HAVE SEX WITH MEN (MSM) (HPTN 069/ACTG A5305)

Roy M. Gulick(New York University), Kenneth H. Mayer(Miriam Hospital), Timothy Wilkin(Cornell University), Robert A. Salata(Case Western Reserve University), Jason E. Farley(Johns Hopkins University), Raphael J. Landovitz(APLA Health), Adriana Andrade(Johns Hopkins University), Marybeth McCauley(Family Health International 360), James F. Rooney(Gilead Sciences (United States)), Craig W. Hendrix(Unknown), Albert Liu(San Francisco Department of Public Health), Karin L. Klingman(National Institutes of Health), Paul Richardson(Johns Hopkins Medicine), Ian Frank(Norwegian Womens Public Health Association), Manya Magnus(Milken Institute), Wairimu Chege(National Institutes of Health), Ken Ho(University of Pittsburgh), Susan H. Eshleman(Johns Hopkins University), Mark A. Marzinke(Family Health International 360), Ying Qing Chen(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Cheryl Marcus(University of North Carolina at Chapel Hill), Joanne D. Stekler(University of Washington), P. Andrew(Family Health International 360), K. Rivet Amico(University of Cape Town), Alex R. Rinehart, Jorge Santana(University of Puerto Rico System), Leslie Cottle(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Alicia Young(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Ian McGowan(University of Pittsburgh)

The Journal of Infectious Diseases

October 31, 2016

Cited by 47

|New England Journal of Medicine|2011|7k

|New England Journal of Medicine|2012|3.3k

|New England Journal of Medicine|2020|2.4k

|New England Journal of Medicine|1997|1.9k

|New England Journal of Medicine|2016|1.7k

Related Papers